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To my Mother 
  
  
ABSTRACT 
The LXRs are important sensors and regulators of cholesterol homeostasis in several 
metabolic tissues including liver, intestine and macrophages. They regulate target genes 
involved in cholesterol-, lipid- and carbohydrat metabolism. Recently, the LXRs have emerged 
as important regulators of the innate and adaptive immune system and inflammation. In this 
thesis we have extend the knowledge of the specific coregulator requirement of LXR in 
cholesterol metabolism and the anti-inflammatory actions of LXR and LRH-1 in the hepatic 
acute phase response. Moreover, we also suggest that LXRs protects against the development of 
colitis. 
In Article I we show that RAP250 has a critical role in the canonical TGF-β pathway and 
interacts with the intracellular mediators, Smad2 and Smad3. The interaction between RAP250 
and Smad2/3 is dependent upon the second LXXLL motif in RAP250 and the MH2 domain in 
Smad2/3. Moreover, activation of the TGF-β and LXR signaling pathways synergistically 
regulates the expression of the LXR target gene ABCG1. Thus, the cross talk between LXR and 
TGF-β could play an important role in the cholesterol efflux pathway. 
In Article II we demonstrate that LXR and the transcriptional co-regulator GPS2 
mediates promoter specific induction of ABCG1 expression and subsequently increased 
cholesterol efflux from macrophages. GPS2 is selectively required for LXR induced 
transcription of ABCG1 and depletion of GPS2 diminishes ABCG1-mediated cholesterol efflux 
in macrophages. GPS2 and LXR authorise histone 3 lysine 9 demethylation-coupled activation 
of ABCG1. Activation and recruitment of LXR to regulatory LXR binding sites (LXRE) in the 
ABCG1 gene induce a communication between the promoter and the enhancer LXRE in the 
ABCG1 gene. Additionally, LXR and GPS2 interactions appear to be AF-2 independent, thus 
separated from the classical LXXLL interaction domain of common LXR transcriptional co-
regulators.  
In Article III we show that LXRs and LRH-1 dampened the hepatic acute phase 
response. This was due to ligand dependent SUMOylation of LXR and LRH-1, which further 
prevented the dissociation of the NCoR corepressor complex where GPS2 mediates the 
interaction between SUMOylated NRs and the NCoR corepressor complex. GPS2 binds to 
SUMO-1 and SUMO-2 via a domain located in the N-terminal part of GPS2, suggesting that 
SUMOylated LXR and LRH-1 bind to the corepressor complex via docking to GPS2 and this 
interaction depends on both the SUMO molecule and the receptor. Moreover, transrepression 
by LXR appears to exclude the heterodimeric partner RXR and in vivo data suggest that LXRβ 
selectively inhibits hepatic APR.  
In Article IV we report that the LXRs protect against DSS-induced colitis in mice. 
Clinical markers of colitis including weight reduction, colon length and diarreha were 
significantly more severe in LXRβ-/- and LXRαβ-/- mice compare to the wild type (WT) control 
mice. Further, LXRαβ-/- mice recovered more slowly from the colitis symptoms compared to 
WT mice. Activation of LXR in human colon cells under inflammatory conditions repressed 
the expression of several pro-inflammatory factors and LXR is recruited to the promoter of 
inflammatory genes. The above- mentioned data could be the reason for the increased 
infiltration of macrophages seen in LXR KO mice and the more severe immune response to 
DSS treatment in LXR KO compared to WT mice.  
In summary, our studies have identified novel molecular mechanisms of LXR 
signaling in metabolism and inflammation. Modulation of LXR activity affects the expression 
profiles of both metabolic pathways and inflammatory signaling pathways. Our observations 
support the notion that LXRs are attractive drug targets for therapeutic intervention of 
metabolic disorders and inflammatory diseases. 
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1 INTRODUCTION 
1.1 NUCLEAR RECEPTORS 
The nuclear receptor (NR) family is a large family of ligand induced 
transcription factors comprising 48 members in humans. Compounds such as thyroid 
hormones, steroids, fatty acids and cholesterol derivates regulate gene expression by 
binding to, and thereby, activating the receptors. NRs regulate several vital processes 
in the body such as development, metabolism, cell growth and reproduction and 
numerous pathological conditions are linked to these receptors such as 
atherosclerosis, hyperlipidemia, obesity, insulin resistance and type 2 diabetes 
(Francis et al. 2003). The NR superfamily can be divided into six subfamilies 
according to functional and sequence homologies. The largest subfamily (NR1) 
includes the liver X receptors (LXR), peroxisome proliferator-activated receptors 
(PPAR), thyroid receptors (TR), retinoic acid receptors (RAR) and the RAR-related 
orphan receptors (ROR), among others. NR subfamily 1 group H includes LXRα 
(NR1H3), LXRβ  (NR1H2), FXRα (NR1H4), FXRβ (NR1H5) and the ecdysone 
receptor (NR1H1), which is found in arthropods (Gronemeyer et al. 2004; Germain et 
al. 2006).  
The mechanisms of action of NRs are in principle similar but there are some 
variations. The ligand can be generated differently; it may be synthesized within the 
cell, generated from a pro-hormone or a precursor within the cell or derived from an 
endocrine organ and transported in the bloodstream to the target cell. Most NRs can 
both activate and inhibit target gene expression and various classical steroid receptors 
are in an inactivate state associated with heat shock proteins and dissociate from the 
complex upon ligand binding and translocate in to the nucleus and bind to DNA at 
specific sequences called hormone response elements (HREs). A subset of NRs is 
assumed to be constitutively nuclear with the NR bound to the HRE on the DNA and 
associated with corepressors in the absence of ligand. Upon binding of ligand the 
repressor complex dissociates from the receptor and different coactivator complex are 
recruited in order to activate the target gene expression. Inhibition of target genes by 
ligand induced NRs involves different tethering mechanisms (no direct DNA binding) 
and several NRs have been shown to transrepress inflammatory target genes (Pascual 
and Glass 2006).   
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NRs display a distinct domain organization and specific functions can be 
assigned to certain sequences within the receptor. A variable N-terminal A/B domain, 
which usually contains an activation function 1 (AF-1), a highly conserved C domain, 
with two ”zinc fingers” creating the DNA binding domain (DBD), a D domain 
including the hinge region, which is very flexible, thus allowing for rotation of the 
DBD, a multifunctional E domain, which mediates ligand binding (LBD), activation 
function 2 (AF-2) and a dimerization surface, and, finally, the F region with the C-
terminal tail (Giguere 1999). The binding of coregulators to NRs is often mediated via 
interactions through AF-1 and AF-2. Most studies have focused on the interactions 
through AF-2, which targets several coregulators in a ligand dependent fashion via a 
signature motif (NR-box) displayed on the protein. In contrast, proteins that bind to 
AF-1 do not share any common motif (i.e. NR-box) (Warnmark et al. 2003). Today 
numerous crystal structures of the LBD and DBD of NRs have been elucidated. The 
LBD shares an overall structure with 12 α helices (H1-H12) and one antiparallel β-
turn. Upon binding of ligand, the receptor undergoes a conformational change from apo 
(no ligand) to holo (liganded) form. This change mainly involves H12 (core of AF-2), 
which leans over the ligand cavity and seals it upon ligand binding. It is mainly held in 
place by hydrophobic interactions, which are indispensable to create an appropriate 
surface that is required for efficient interaction with different coregulators binding to 
AF-2 (Bourguet et al. 2000; Egea et al. 2000).  
 
 
 
1.2 THE LIVER X RECEPTORS  
The liver X receptors, LXRα (NR1H3) and LXRβ (NR1H2) generally function 
as permissive heterodimers with Retinoid X Receptor (RXR). LXRα and LXRβ bind to 
a specific DNA sequence, called LXR response element (LXRE), which consists of 
direct repeats of the consensus halfsite sequence 5´-AGGTCA-3´ where the halfsites 
are spaced by four nucleotides (DR-4 motif) (Zelcer and Tontonoz 2006). LXRα was 
originally cloned by Apfel et al., with high expression in liver, kidney, intestine, 
macrophages and adipose tissue (Apfel et al. 1994; Willy et al. 1995). LXRβ was 
isolated and characterised by several groups the same year and is ubiquitously 
expressed (Shinar et al. 1994; Song et al. 1994; Teboul et al. 1995). Human LXRα (447 
amino acids) and LXRβ (460 amino acids) share 77% sequence homology in the DBDs 
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and LBDs and structural studies of the LBD of the LXRs have revealed a canonical NR 
structure (Bourguet et al. 1995; Renaud et al. 1995; Bourguet et al. 2000; Farnegardh et 
al. 2003; Williams et al. 2003). The natural endogenous ligands for LXRs are 
oxysterols, which are oxidized derivates of cholesterol, including 24(S)-
hydroxycholesterol, 22(R)-hydroxy-cholesterol and 24(S), 25-epoxycholesterol 
(Janowski et al. 1999; Shibata and Glass 2010). Through structure activity relationship 
studies there are also synthetic ligands for the LXRs available today, such as T0901317 
(N-(2,2,2-tri-fluoroethyl)-N-[4-(2,2,2-tri-fluoro-1-hydroxy-1-tri-fluoro-methyl-ethyl)-
phenyl]-benz-enesulfon-amide), GW3965, Acetyl-podocarpic dimer (APD), N-
acylthiadiazolines (LXRβ-selective) and sulfonamide GSK2033 (antagonist) (Schultz 
et al. 2000; Collins et al. 2002; Sparrow et al. 2002; Chao et al. 2008; Zuercher et al. 
2010). The best characterised and used synthetic ligands include GW3965 and 
T0901317.  
The LXRs are key regulators of cholesterol metabolism, displaying anti-
atherogenic properties, through regulation of various proteins involved in cholesterol 
transport from peripheral tissues to the liver. Studies also highlight the importance of 
these receptors in hepatic lipogenesis by induction of fatty acid and triglyceride 
biosynthesis (mainly via LXRα) through direct regulation of the sterol regulatory 
element-binding protein 1c (SREBP-1c), fatty acid synthase (FAS) and stearoyl-CoA 
desaturase 1 (SCD1). Activation of LXR also reduces the expression of several 
enzymes involved in hepatic gluconeogenesis such as, glucose 6-phosphatase (G6Pase), 
fructose 1,6-bisphosphatase, phosphoenolpyruvate carboxykinase (PEPCK) and 
pyruvate carboxylase, thus improving the glucose tolerance. Additionally, the glucose 
transporter 4 (GLUT4) is regulated by LXRs in white adipose tissue, stimulating the 
uptake of glucose in this tissue.  The anti-atherogenic action of LXR is most likely 
linked to the emerging anti-inflammatory properties associated to these receptors. In 
addition, growing amount of data also suggest additional roles for LXRs in the innate 
and adaptive immune response.  
The impact of LXR and coregulators in cholesterol metabolism and inflammation 
will be covered in further detail below. 
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1.3 CHOLESTEROL METABOLISM 
1.3.1 HDL metabolism 
It is well established today that high density lipoproteins (HDLs) display anti- 
atherogenic properties and presumably anti-inflammatory functions through various 
complex mechanisms (Rader 2006). The main function of HDL is transport of lipids in 
the blood, which involves several complex steps. Formation of HDL is initiated 
through synthesis of apoA-I from the liver and intestine, which subsequently undergoes 
lipidation (addition of cholesterol and phospholipids), via ATP-binding cassette 
transporter A1 (ABCA1) expressed on the enterocytes and hepatocytes, forming lipid 
poor HDL particle. From the peripheral tissues, lipid poor HDL promotes efflux of free 
cholesterol through ABCA1 and subsequently the mature HDL particle is formed via 
ABCG1. Maturation of HDL requires esterification of cholesterol through the enzyme 
lechitin: cholesterol acyltransferase (LCAT). The mature HDL particle is returned to 
the liver and uptake of cholesterol is mediated through the scavenger receptor class BI 
(SR-BI). Alternatively, cholesterol is transferred to LDL particles through the 
cholesteryl ester transfer protein (CETP) and taken up by the liver via binding of the 
LDL particles to the hepatic LDL receptor (LDLR). In the liver cholesterol is 
hydrolysed to free cholesterol, which is converted to bile acids or secreted to the bile 
duct (Rader 2006; Rader and Daugherty 2008).   
 
 
1.3.2 The ABC-transporters 
 The ATP-binding cassette (ABC) transporters are a family of transmembrane 
proteins, which comprise of more than 250 proteins and transport different substrates 
through the cell membrane such as, bile acids, sterols, phospholipids and peptides, in a 
process requiring hydrolysis of ATP. The efflux of cholesterol from cells is regulated 
by the transporters ABCG1, ABCA1, ABCG4, ABCG5 and ABCG8, all regulated by 
LXR (Baldan et al. 2009). The importance of ABCA1 in cholesterol metabolism was 
shown in 1999 in patients with Tangier disease. These patients have mutations in the 
ABCA1 gene and exhibit little or no plasma HDL (Brooks-Wilson et al. 1999; Marcil 
et al. 1999; Rust et al. 1999). Moreover, ABCA1 deficient mice accumulate cholesterol 
in macrophages and have increased expression of pro-inflammatory cytokines when 
challenged with LPS (Zhu et al. 2008). The human ABCG1 (Chen et al. 1996; Croop et 
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al. 1997) is expressed in many cell types and was originally shown to be involved in 
lipid transport from macrophages (Klucken et al. 2000). Recently, several groups have 
shown that ABCG1 together with ABCA1 is important for efflux of cholesterol from 
macrophages to mature HDL particles (Wang et al. 2004; Kennedy et al. 2005; Wang et 
al. 2007; Yvan-Charvet et al. 2007). The ABCG5/G8 transport cholesterol from the 
liver to the bile duct and from the intestine limiting cholesterol uptake from the diet. 
Cholesterol and plant sterols are absorbed in the intestine via the Niemann Pick C1-like 
protein (NPC1L1) and the majority of cholesterol is esterified in the enterocytes, 
whereas some cholesterol and plant sterols are extruded back to the intestinal lumen 
through ABCG5/G8. Mutations in ABCG5/G8 can cause sitosterolemia, which is a 
genetic disorder characterised by increased levels of plant sterols, due to an impaired 
regulation of sterols in the intestine and liver (Oram and Vaughan 2006). The 
importance of ABCG5/8 in cardiovascular disease has been shown using ABCG5/8 
transgenic mice expressing high levels of G5 and G8, which display reduced plasma 
cholesterol levels and aortic lesion area upon western diet (Wilund et al. 2004).  
 In addition to the well-known function of ABCA1 and ABCG1 in development 
of atherosclerosis, it has become evident that these transporters have roles linked to the 
inflammatory response. Several studies have shown that ABCG1 and ABCA1 deficient 
mice display enhanced inflammatory response when challenged with LPS highlighting 
the importance of these transporters in the above-mentioned pathways (Yvan-Charvet 
et al. 2007). 
 
 
 
1.4 LXR AND CHOLESTEROL METABOLISM  
The LXRs are important sensors and regulators of cholesterol homeostasis in 
several metabolic tissues including liver, intestine and macrophages and regulate a 
variety of target genes encoding diverse enzymes involved in cholesterol synthesis, 
metabolism, absorption, and transport (Zelcer and Tontonoz 2006). Early in vivo 
evidence demonstrated the importance of the LXRs in cholesterol metabolism using 
LXRα-/- mice, which when fed with high cholesterol diet accumulated large amounts of 
cholesterol in the liver due to impaired regulation of the enzyme cholesterol 7α-
hydroxylase (Cyp7A1), the rate-limiting enzyme converting cholesterol to bile acids 
(Peet et al. 1998). This phenotype is restricted to LXRα-/- and is not seen in LXRβ-/- 
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mice (Alberti et al. 2001). Shortly after, it was recognized that LXR has anti-
atherogenic potential by inhibiting the progression and even promoting the regression 
of atherosclerosis (Joseph et al. 2002; Schuster et al. 2002; Tangirala et al. 2002), 
which has later been established in several different mouse models (Calkin and 
Tontonoz 2010).   
Subsequent reports have demonstrated regulation of several LXR target genes 
involved in cholesterol metabolism. The cholesterol ester transfer protein (CETP), 
which facilitates transfer of cholesterol esters from mature HDL to apoB containing 
lipoproteins and clearance via the liver, is positively regulated by LXR both in vitro 
and in vivo in transgenic mice expressing human CETP (Honzumi et al. 2010; Luo and 
Tall 2000). LXREs have been identified and characterised in the proximal promoter of 
phospholipid transfer protein (PLTP) and shown to be functional using T0901317 in 
macrophage cell cultures (Mak et al. 2002). Moreover, Lafitte et al. have demonstrated 
that both PLTP and apolipoprotein E (apoE) are regulated in peritoneal macrophages 
by LXR activation and that the expression of both PLTP and apoE is reduced in LXR 
deficient animals (Laffitte et al. 2001; Laffitte et al. 2003).  
Besides the liver, the intestine is important for synthesis of apoA-I and generation 
of lipid poor HDL particles via efflux of phopholipids and cholesterol. Recently, using 
mice lacking ABCA1 in the intestine, Brunham et al. reported that approximately 30% 
of the plasma HDL is derived from the intestine and that ABCA1 is an important factor 
involved in HDL biogenesis (Brunham et al. 2006a). Moreover, activation of LXR in 
mice lacking hepatic ABCA1 significantly raises plasma HDL, thus supporting the idea 
that intestinal ABCA1 is important for biogenesis of plasma HDL (Brunham et al. 
2006b). Lo Sasso et al, recently presented data using constitutively activated LXRα in 
the intestine, which reduced the cholesterol absorption and increased the levels of lipid 
poor HDL in mice feed atherogenic western diet. Moreover, these mice also displayed 
antiatherogenic effects, revealed by reduced atherosclerotic lesions (Lo Sasso et al. 
2010). In addition to regulating the expression of ABCA1 in the intestine, LXR also 
regulates the expression of ABCG5 and ABCG8 in the intestine and the liver. 
Activation of LXR in mice, and likely in humans (Jiang et al. 2008), up regulates the 
expression of ABCG5/8 and downregulates the expression of NPC1L1, consequently 
increasing the sterol secretion from the liver and decreasing the absorption of 
cholesterol in intestine, thus regulating the efflux of cholesterol (Lo Sasso et al. 2010; 
Repa et al. 2002; Yu et al. 2003).  
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One of the major efflux pathways from macrophages and a well established 
protective mechanism against atherosclerosis is the transport of cholesterol to the liver 
(reverse cholesterol transport (RCT)) via ABCA1 and ABCG1, both regulated by LXR 
and this pathway has been studied intensively. (Costet et al. 2000; Repa et al. 2000; 
Schwartz et al. 2000; Venkateswaran et al. 2000; Kennedy et al. 2001; Kennedy et al. 
2005). Notably, activation of LXR in vivo, using different mouse models, has been 
shown to increase the rate of RCT from macrophages via ABCG1 and ABCA1 (Naik et 
al. 2006; Wang et al. 2007; Yvan-Charvet et al. 2007). Additionally, a recent study 
reported that an intestinal specific LXR agonist promotes RCT in macrophages in vivo, 
Figure 1. Role of LXRs in HDL metabolism and cholesterol efflux. Activation of LXR 
increases the expression of the cholesterol-transporters ABCA1 and ABCG1 in 
macrophages, subsequently increasing the efflux of cholesterol from macrophages, a 
process known as reverse cholesterol transport. ABCA1 transports cholesterol to lipid-poor 
APO-AI-HDL and ABCG1 to mature HDL. HDL is transported to the liver via SR-B1 and in 
the liver LXR promotes the excretion of cholesterol, via ABCG8/5 and conversion to bile 
acids through regulation of Cyp7a1 (in rodent), to the bile duct. Activation of LXR also 
promotes the transport of APO-AI, via upregulation of ABCA1 in the liver and intestine, to 
generate APO-AI-HDL. In the intestine LXR limits the uptake of cholesterol through 
activation of ABCG8/G5.  
  8 
thus emphasizing the importance of LXRs in both intestine and macrophages (Yasuda 
et al. 2010). Hematopoietic stem cell (HSC)-based LXRα-gene delivery into 
macrophages in LDLR-/- mice fed western diet appears to reduce the atherosclerotic 
lesions as well as plasma triglyceride levels and inflammatory cytokines (Li et al. 
2011), again highlighting the importance of selective activation of LXR in extrahepatic 
tissues, to circumvent increased levels of triglycerides in liver and plasma.  
 
 
 
1.5 THE IMMUNE SYSTEM AND INFLAMMATION 
1.5.1 The innate and the adaptive immune response 
The body’s defence against microbes and other foreign substances is mediated 
by the early response called innate immunity and subsequently the slower adaptive 
response. The innate immunity or “the first defence” is rapid and consists of 4 different 
components: 1⎠ the epithelial barrier, 2⎠ circulating effector cells (neutrophils, 
monocytes (macrophages) and natural killer (NK) cells), 3⎠ cytokines and 4⎠ the acute 
phase response including the complement system (Rosen 2000). The function of the 
effector cells is to detect the microbes and through secretion of cytokines stimulate the 
inflammatory response. The detection of pathogens is mediated via pattern recognition 
receptors (Toll-like receptors (TLRs)) and others, which detect various molecular 
patterns including bacterial DNA, lipoproteins, lipopolysaccharide (LPS) and viral 
DNA (Ishii et al. 2008). The major source of cytokines in the innate immunity is 
neutrophils, macrophages and NK cells. The expression of cytokines is a complex 
network of pleiotropic effects, to ensure diverse effects in the host. Most often this 
response is rapid and transient and operates both systemically and locally.  
The adaptive immunity (acquired immunity) is mediated by lymphocytes, so 
called B cells and T cells (cytotoxic and helper). In response to recognition of different 
antigens the T cytotoxic cells become activated and the antigen presenting cells are 
removed by lysis or apoptosis. In addition to T cytotoxic cells, T helper cells become 
activated during the acquired response and release cytokines for subsequent activation 
of other cell types involved in the immune response. The B cells produce antibodies 
targeting antigens for subsequent phagocytosis and activate the complement system. A 
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small fraction of the B cells becomes memory cells in order to respond quickly and 
produce antibodies if the same antigen re-infects the host (Rosen 2000).  
 
     
1.5.2   TGF-β signaling 
The cytokine transforming growth factor β (TGF-β) is a pleiotropic factor and 
regulates a diverse set of cellular responses, such as cell proliferation, apoptosis and 
different immunomodulatory functions (Li et al. 2006) and dysregulation of TGF-β is 
linked to several diseases, such as atherosclerosis, cancer and different fibrotic diseases 
(Blobe et al. 2000).  TGF-β binds to surface receptors and the canonical signaling 
cascade includes phosphorylation and the subsequent activation of Smad transcription 
factors (Sequence similarity to Sma (C.elegans) and Mad (Drosophila) proteins). In 
addition, TGF-β also activates several protein kinase pathways (Massague et al. 2005).    
Recent in vitro and in vivo studies have shown that activation of the TGF-β 
pathway appears to be anti-atherogenic (Robertson et al. 2003), via increased 
cholesterol efflux, among other mechanisms, through upregulation of ABCA1 and 
ABCG1 (Argmann et al. 2001; Panousis et al. 2001).  
Given the plethora of effects, not surprisingly, crosstalk between the TGF-β 
pathway, Smad dependent and independent, and NR signaling has been described for 
several receptors, such as GR, ER and the PPARs (Song et al. 1999; Matsuda et al. 
2001; Stockert et al. 2011).  
 
 
1.5.3 The acute phase response  
The acute phase response (APR) is a systemic reaction that is initiated by local 
or systemic disturbance caused by infection, inflammation, surgery, trauma and 
neoplasia. The function of the APR is to prevent microbial growth, restore homeostasis 
and promote healing. Upon the APR several pro-inflammatory cytokines are released, 
mainly from monocytes and macrophages, including interleukin 6 (IL-6), inteleukin 1β 
(IL-1β) and tumor necrosis factor α (TNFα) (Moshage 1997; Gabay and Kushner 
1999). The overall aim of the cytokines is to stimulate production of acute phase 
proteins (APPs), which are primarily produced in hepatocytes and regulated via pro-
inflammatory factors such as signal transducer and activator of transcription (STAT) 3, 
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CCAAT-enhancer binding protein (C/EBP) β, activator protein (AP) 1 and nuclear 
factor kappa B (NFκB). However, certain APPs are produced in adipose tissues under 
low-grade inflammatory conditions (e.g. obesity) (Yang et al. 2006; Poitou et al. 2009; 
Zhao et al. 2010). During the acute phase response, positive and negative APPs are 
rapidly synthesised and transported to peripheral tissues and the main positive APPs 
include serum amyloid A (SAA), c-reactive protein (CRP), haptoglobin and 
plasminogen activator inhibitor-1 (PAI-1). The function of most APPs has not fully 
been elucidated, however the above-mentioned APPs play important roles in different 
metabolic changes during APR. The first described APP was CRP (Tillett and Francis 
1930), known to activate the complement system and its ability to recognize pathogens. 
SAA is an apolipoprotein like protein and participates in cholesterol metabolism and 
induces cytokine production in endothelial cells. Moreover, chronically elevated levels 
of SAA in adipose tissue have been linked to obesity. Haptoglobin has anti-
inflammatory properties and binds haemoglobin, and like SAA is linked to cholesterol 
metabolism (Gruys et al. 2005).  
During the APR major metabolic changes, such as cholesterol and triglyceride 
synthesis and alterations in HDL associated cholesterol transport occurs (Khovidhunkit 
et al. 2004). The plasma levels of HDL decrease and the major apolipoprotein of 
normal HDL (apolipoprotein AI) is replaced by SAA. The acute phase HDL (SAA-
HDL) has different composition compared to normal HDL and is believed to be pro-
atherogenic and the altered properties of acute phase HDL have significant impact on 
cholesterol transport and cholesterol efflux (Feingold and Grunfeld 2010; Jahangiri 
2010; King et al. 2010). Several studies indicate that SAA-HDL impairs cholesterol 
efflux (Banka et al. 1995; McGillicuddy et al. 2009; Annema et al. 2010), however 
there are contradictory reports showing that SAA-HDL increases cholesterol efflux 
due to enhanced acceptor capabilities of acute phase HDL (Tam et al. 2005; Tam et 
al. 2008). One explanation for the increased efflux capability of acute phase HDL 
might involve the regulation of acyl-CoA: cholesterol acyl transferase (ACAT) and 
cholesteryl ester hydrolase (CEH) by SAA-HDL. Studies have shown that SAA 
suppresses the expression of ACAT and stimulates the expression of CEH in 
cholesterol-laden macrophages, consequently, reducing the pool of cholesterol esters 
and increasing the pool of free cholesterol available for transport to HDL acceptors 
via ABC-transporters (Tam et al. 2002; Kisilevsky and Tam 2003).  
A recent series of investigations has identified liver receptor homolog-1 (LRH-
1) as a negative regulator of the hepatic APR (Venteclef et al. 2006; Venteclef and 
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Delerive 2007). Overexpression of LRH-1 in hepatocytes was reported to result in a 
strong inhibition of both IL-6 and IL-1β-stimulated expression of SAA, haptoglobin, 
and fibrinogen. Negative regulation appeared to involve direct transcriptional crosstalk 
of LRH-1 with C/EBPβ, in part via inhibition of DNA-binding. In addition to LRH-1, 
PPARs were early linked to the hepatic APR (Gervois et al. 2001; Kleemann et al. 
2004; Zambon et al. 2006; Mansouri et al. 2008). Both PPARα and δ are expressed in 
hepatocytes where they regulate multiple pathways involved in fatty acid and glucose 
metabolism. Direct transcriptional interference with pro-inflammatory factors such as 
NFκB and C/EBP has been suggested as a plausible mechanism. A notable exclusion is 
the glucocorticoid receptor (GR), which acts anti-inflammatory in immune cells but is 
a positive modulator of APR gene expression in the liver (Wang et al. 2001). 
 
 
1.5.4 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) includes Crohn´s disease (CD) and 
ulcerative colitis (UC) and the causes behind IBD are believed to be environmental 
factors, the luminal flora and genetic predisposition (Loftus 2004). Moreover, studies 
have shown that increased permeability of the epithelial layer to some extent might 
contribute to the progress of IBD (Hermiston and Gordon 1995; Buhner et al. 2006). 
The inflammatory regions include ileum, colon and rectum and are most often 
accompanied by development of mucosal ulceration together with infiltration of a 
complex mixture of both innate and adaptive immune cells (Abraham and Cho 2009). 
The infiltration of the immune cells is mediated via TLRs expressed on the epithelium 
and nucleotide oligomerisation domain (NOD) proteins expressed in dendritic cells and 
epithelial cells (Rakoff-Nahoum et al. 2004; Strober et al. 2006; Vijay-Kumar et al. 
2007). Activation of TLR and NOD increases the activity of NFκB which in turn 
increases the expression of numerous cytokines and chemokines such as IL-10, IL-6, 
TNF-α, IL-1β, IL-12, IL-23, IL-8 and TGF-β. This response activates the adaptive 
response, which includes different subsets of T helper cells (Th1, Th2 and Th17) and 
their differentiation is determined by different cytokines (Hue et al. 2006; Abraham and 
Cho 2009). Historically, IBD have been viewed as a T-cell driven disease but 
increasingly more evidence also suggest important functions of the innate response.     
The NRs are becoming an attractive alternative for treatment of inflammatory 
conditions as several of the NRs have been identified as potent anti-inflammatory 
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factors. Many studies have reported that different NRs protects against IBD in mice. 
PPARγ was shown to suppress development of dextran sulfate sodium (DSS) induced 
colitis in mice and trinitrobenzene sulfonic acid (TNBS) induced colitis in rats 
(Ramakers et al. 2007; Sanchez-Hidalgo et al. 2007). Interestingly, the protective 
function of PPARγ appears to be mediated by its anti-inflammatory role in both colonic 
epithelium (Adachi et al. 2006) and macrophages associated with colitis-induced 
inflammation (Shah et al. 2007b). Likewise, activation of the farnesoid X receptor 
(FXR) protects against DSS and TNBS induced colitis in mice; a mechanism also due 
to suppression of inflammatory responses. However, it is unclear if lack of FXR 
increases the predisposition to colitis as one report supports this (Vavassori et al. 2009) 
while the other does not (Gadaleta et al. 2011). Activation of the pregnane X receptor 
(PXR) was shown to ameliorate DSS-induced colitis in mice, apparently via repression 
of the NF-κB signaling pathway (Shah et al. 2007a). Heterozygous knock out mice for 
the LRH-1 had increased inflammatory response to TNBS-induced colitis, which was 
due to its transcriptional regulatory mechanisms of genes involved in glucocorticoid 
production in the intestine (Coste et al. 2007).  
 
 
 
1.6  LXR AND THE IMMUNE SYSTEM 
In addition to the well-known functions of LXR in lipid metabolism, the LXRs 
have expanded their repertoire and emerged as important factors in the innate and 
adaptive immune system and inflammation (Zelcer and Tontonoz 2006). The anti-
inflammatory activities of LXR were first described 2003 using a cutaneous 
inflammatory mouse model, in which activation of LXR using GW3965 or 22-
hydroxycholesterol inhibited the expression of TNFα and IL-1α (Fowler et al. 2003). 
The first evidence linking cholesterol metabolism and the innate immunity through 
LXR were described the same year. These studies provided evidence using LPS 
stimulated macrophages, that ligand activated LXR inhibits the expression of several 
inflammatory factors, such as interleukin 6 (IL-6), cyclooxygenase 2 (COX-2) and 
inducible nitric oxide synthase (iNOS). Moreover, they also showed that activation of 
TLR (TLR3/4) signaling compromised several LXR target genes, such as ABCA1 and 
ABCG1, and consequently the cholesterol efflux via the transcription factor interferon-
regulatory factor 3 (IRF3), connecting cholesterol and innate immune signaling to LXR 
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function (Castrillo et al. 2003; Joseph et al. 2003). The transrepressive mechanism 
behind the anti-inflammatory action of LXR and other nuclear receptors as well, was 
originally described by Glass and co-workers (Ricote et al. 1998; Pascual et al. 2005) 
and will be discussed in further detail below (1.7.2.1). Studies have also shown that 
LXR regulates macrophage survival. Using bone marrow derived macrophages from 
LXR deficient mice infected with different bacterial pathogens, it has been shown that 
these cells are more susceptible to bacterial infection and exhibit accelerated apoptosis. 
Moreover, activated LXR induces the expression of several anti-apoptotic factors, such 
as AIM, Bcl-XL and Birc1a and inhibits several proapoptotic factors including several 
caspases, consequently preventing bacterial induced apoptosis (Joseph et al. 2004; 
Valledor et al. 2004).  
A role in host defence has recently been described for LXR in the lungs. Using 
different in vivo models several groups have shown that activation of LXR in lung 
tissue macrophages reduces the inflammatory response, induced by LPS and Klebsiella 
pneumoniae, and diminishes the influx of neutrophils to the lungs (Birrell et al. 2007; 
Smoak et al. 2008). The anti-inflammatory response of LXR might depend on the 
pathogen, as suggested by a group using LXR deficient mice infected with 
Mycobacterium tubercolosis. This study revealed that these mice were more susceptible 
to infection compared to WT animals and exhibited a defective neutrophil response 
(Korf et al. 2009).  
Several data also suggest additional functions of LXR in dendritic cells and T-
cells, thus linking LXR both to innate and adaptive immunomodulatory functions. LXR 
activation has been described to hamper LPS induced human myeloid dendritic cell 
(DC) maturation and function, which in turn blocks the ability of DC to activate T-cells 
(Geyeregger et al. 2007). Recently, using different tumor models, one study showed 
that both human and mouse tumors produces endogenous LXR ligands, which inhibit 
the expression of CC chemokine receptor-7 (CCR7) on maturing DC, thus impairing 
the antigen presenting function to T- and B-cells. Furthermore, viral knock down of 
LXRα in human hepatocarcinoma cell lines prevents CCR7 inhibition by 22- 
hydroxycholesterol. Collectively, this data suggests that that activation of LXR in DC 
inhibits the antitumor immune response via a reduced migration to lymphoid organs 
and reduced activation of the adaptive response (Villablanca et al. 2010).  
Activated LXR also appears to have anti-proliferative effect in T-cells, which 
seems to be coupled to the cellular levels of sterols and regulation of the LXR target 
gene ABCG1. During T-cell proliferation, expression of the enzyme sulfotransferase 
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family cytosolic 2B member 1 (SULT2B1) is increased, which consequently 
inactivates the endogenous LXR ligands in T-cells and downregulates several LXR 
target genes including ABCG1. The downregulation of ABCG1 seems to be a key 
component given the fact that LXR in lymphocytes from ABCG1 deficient mice 
displays reduced capability to inhibit proliferation compared to WT mice (Bensinger et 
al. 2008). 
The hallmark of the neuro-inflammatory disease, Alzheimer’s disease, is 
deposition of amyolid β (Aβ) plaques; the formation of Aβ decreases during cellular 
cholesterol depletion. Not surprisingly, given the known function of LXR linked to 
inflammation and cholesterol metabolism, several groups have suggested important 
roles for LXR in Alzheimer’s disease. Activation of LXR, in vitro and in vivo, using 
T0901317 in neural cells and APP23 transgenic mice has been shown to decrease the 
levels of Aβ through upregulation of the LXR target gene ABCA1. Moreover, Tangier 
disease derived fibroblasts lacking functional ABCA1 have increased formation of Aβ, 
thus linking activation of LXR via ABCA1 to decreased levels of Aβ (Sun et al. 2003; 
Koldamova et al. 2005). Above-mentioned studies where recently confirmed using 
LXR deficient mice (Genetic loss of Lxra or Lxrb in APP/PS1 mice), which displayed 
increased levels of amyolid plaques compared to WT mice. Furthermore, several LPS 
induced inflammatory factors in primary microglial cells were repressed with GW3965 
and this anti-inflammatory effect increased the phagocytic capacity of these cells, 
suggesting an increased clearence of Aβ (Zelcer et al. 2007).  
Most studies have primarily focused on the anti-inflammatory actions of LXR in 
different cell-types of the immune system. In addition, ligand activated LXR displays 
anti-inflammatory actions in the liver, repressing the expression of APPs, including 
CRP and SAP (Blaschke et al. 2006), although the mechanism behind this effect is 
unknown.  
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1.7 NUCLEAR RECEPTORS AND COREGULATORS IN 
TRANSCRIPTIONAL REGULATION   
1.7.1 Transcriptional regulation by NRs 
Nuclear receptors recruit a large number of coregulatory proteins in order to 
regulate transcription. Coregulators function as bridging and/or stabilizing factors, 
inhibitors of specific protein-protein interactions or modifiers of other proteins with 
different enzymatic activity, such as acetylation/deacetylation, methylation /de-
methylation, SUMOylation, ubiquitylation and phosphorylation. These events initiate 
(coactivators) or inhibit (corepressors) chromatin remodelling/structure and/or the 
assembly of the general transcription machinery. Most of the NRs are believed to be 
constitutively nuclear, except the classical steroid receptors, and the traditional model 
of NR dependent regulation of transcription (Figure 2) involves a ligand independent 
interaction with corepressors (e.g. NCoR/SMRT) on DNA. Upon binding of ligand the 
repressor complex dissociates and different coactivators are recruited (Rosenfeld et al. 
2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Classical coregulator exchange mechanism for a subset of NRs. In the absence 
of ligand the NR is present on DNA with corepressors. Binding of ligand induces a 
conformational change on the receptor and the subsequent exchange of corepressors for 
coactivators and activation of target gene expression.   
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A well-studied group of coactivators is the p160 family including, steroid 
receptor coactivator-1 (SRC-1), GR-interacting protein (GRIP1, TIF-2, SRC-2) and 
p300/CBP cointegrator-associated protein (p/CIP, AIB1, SRC-3) and early studies 
identified a signature motif (NR-box), LXXLL (L: Leucine; X: any amino acid), found 
on many NR coactivators, which binds to the AF-2 of ligand activated NRs (Onate et 
al. 1995; Voegel et al. 1996; Anzick et al. 1997; Heery et al. 1997).  
Recent work (epigenomic, genome-wide high-throughput assays) has 
identified additional NR dependent regulatory mechanisms such as, long-range 
chromosomal interactions and histone modifications (e.g. histone methylation 
/demethylation), many of which are dependent on direct or indirect NR-coregulator 
interactions. Generally, acetylation of histones via histone acetyl transferase (HAT) 
activity is believed to be an activation mark of transcription, whereas deacetylation via 
histone deacetylase (HDAC) action is linked to repressive chromatin. Moreover, 
methylation marks on the histones can be assigned to different functions. For example, 
methylation of lysine 4 on histone 3 (H3K4) appears to be linked to activation. 
Furthermore, trimethylation of H3K4 (H3K4me3) is often found at active promoters 
(often associated with a nucleosome free region), whereas active enhancer regions 
appear to require mono/di-methylation at H3K4 (H3K4me1 or H3K4me2) (Heintzman 
et al. 2007; Heintzman et al. 2009). In contrast, methylation of H3K9 induces a 
repressed state. Methylation and demethylation of histones is executed by methylases 
and demethylases and these enzymes have been found to coregulate several NRs in 
transcriptional regulation (Kato et al.). The androgen receptor (AR) has been shown to 
directly interact with the demethylases KDM1 (LSD1), KDM3A (JHDM2A) and 
KDM4C (JMJD2C) in a ligand dependent manner, leading to a demethylation of H3K9 
and consequently activation of transcription (Metzger et al. 2005; Yamane et al. 2006; 
Wissmann et al. 2007). 
In addition to histone modifications recent studies have also identified long-
range chromosomal interactions between NR regulatory elements (i.e promoter-
enhancer interactions). It has been suggested that formation of chromatin loops is 
necessary to activate transcription and that the enhancers are epigenetically marked in 
order to communicate with the promoter for rapid activation of target genes, although 
the mechanisms behind these interactions remain unclear (Ong and Corces 2011). Most 
studies of NRs have primarily focused on the proximal promoters of known NR target 
genes, however, recent genome wide studies from Brown and co-workers suggest that 
most binding sites for ER and AR are found distally from promoters in intronic and 
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intergenic regions (Carroll et al. 2005; Carroll et al. 2006; Lupien et al. 2008), which 
presumably is true for most NRs. Moreover, many ER distal binding sites are anchored 
to ER promoters as revealed by a recent global chromatin interaction study, which 
might function to increase the local concentration of different transcription factors in 
order to regulate the transcription (Fullwood et al. 2009). 
While basic mechanisms of coregulator action are supposed to be preserved 
between LXRs and other NRs, as revealed by early experiments utilising various 
interaction and transient transfection assays, the specific coregulator requirement and 
dynamics of vital LXR target genes remain principally unknown. LXR interacts with 
several typical NR coregulators, such as the p160 family, receptor interacting protein 
140 (RIP140), small heterodimer partner (SHP), NCoR/SMRT, peroxisome proliferator 
activated receptor γ co-activator α (PGC-1α), transformation/transcription domain-
associated protein (TRRAP) and receptor activating protein 250 (RAP250) (Wiebel et 
al. 1999; Lee et al. 2001; Brendel et al. 2002; Hu et al. 2003; Oberkofler et al. 2003; 
Huuskonen et al. 2004; Albers et al. 2005; Unno et al. 2005). Although informative, the 
limitation with transient transfections and interaction studies is that they are performed 
in a nucleosome free environment and mostly in vitro. Wagner et al. addressed this 
issue using the chromatin immunoprecipitation (ChIP) technique to study the promoter 
specific roles of LXR in bone marrow derived macrophages, in which they 
demonstrated that LXR and NCoR/SMRT where recruited to the ABCA1 and SREBP-
1c promoters and repressed the gene expression of ABCA1 in the absence of ligand, 
suggesting promoter specific roles for LXR (Wagner et al. 2003).  Moreover, a current 
study demonstrated that SIRT1 interacts with ligand activated murine LXRs  at the 
ABCA1 promoter and support deacetylation at lysine 433 on LXRβ and 432 on LXRα 
(corresponding to residue 448 in human LXRβ  and 434 in human LXRα). This induces 
a proteasomal degradation of the receptor and promotes cholesterol efflux through 
increased LXR activity and this turnover appears to be essential in the activation 
process as suggested by the authors (Li et al. 2007). To this point, two studies have 
provided genomic binding sites data governing the LXRβ cistrome, ChIP-seq for 
biotin-tagged LXRβ in murine macrophages (RAW264.7) and conventional antibody 
based ChIP-on chip in human epidermal keratinocytes (NHEK). Not surprisingly, most 
LXRβ binding sites were found distally located to the transcription start site and AP-1 
sites were co-enriched close to LXRβ binding sites. Furthermore, in RAW264.7 cells 
PU.1 sites were co-enriched nearby LXRβ binding sites and PU.1 was suggested to 
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function as a pioneer factor for LXRβ (Heinz et al. 2010; Shen et al. 2011). 
Unquestionably, the molecular details of the LXR cistrome/interactome including long-
range chromosomal interactions, histone modifications, LXR subtype diversity and 
tissue/species-specificity (e.g. human macrophages and hepatocytes) are waiting to be 
discovered in the near future.  
 
 
1.7.2 Coregulators  
1.7.2.1 The NCoR/SMRT complex 
Silencing of gene transcription is often linked to deacetylation of histones and 
this enzymatic process is mediated via recruitment of histone deacetylases (HDACs) to 
the chromatin. The histone deacetylase HDAC3 belongs to the NCoR or SMRT 
corepressor complex and these complexes were initially linked to unliganded NR 
mediated repression, hence the names nuclear receptor corepressor (NCoR) and 
silencing mediator of retinoic acid and thyroid receptor (SMRT) (Horlein et al. 1995; 
Alland et al. 1997; Heinzel et al. 1997; Nagy et al. 1997). Unliganded NRs bind to a 
hydrophobic motif on NCoR/SMRT, so called corepressor nuclear receptor (CoRNR) 
box (Hu and Lazar 1999; Perissi et al. 1999). In addition to NRs, the NCoR/SMRT 
corepressor complex can also be recruited to different inflammatory promoters and 
associate with different transcription factors. Mouse models deficient in either the 
NCoR or SMRT gene are embryonically lethal (embryonic day 14.5); NCoR appears to 
be central for the development of erythrocytes and SMRT appears to have important 
cardiovascular functions (Perissi et al.). The NCoR/SMRT/HDAC3 core corepressor 
complexes also contain additional proteins including the transducin β-like proteins 
(TBL1 and TBLR1), G-protein pathway suppressor 2 (GPS2) and coronin 2A 
(CORO2A). Biochemical studies of the core corepressor complex have revealed direct 
interactions between TBL1 and GPS2 and cooperative interactions with the N-terminal 
repression domain 1 (RD1) of NCoR. Moreover, interaction of HDAC3 with NCoR 
appears to be mediated via a deacetylase-activating domain (DAD) that activates 
HDAC3 upon binding to the corepressor complex (Guenther et al. 2000; Li et al. 2000; 
Zhang et al. 2002; Yoon et al. 2003). The interaction between GPS2 (N-terminal) and 
SMRT (RD1) was recently determined by NMR studies and revealed an antiparallel-
coiled coil arrangement, which seems to enhance the binding of these two proteins to 
the N-teminal region of TBL1. Furthermore, this interaction appears to depend on a 
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short helical sequence motif (TBL1 interaction motif) found in both GPS2 and SMRT 
(and NCoR) (Oberoi et al. 2011).  
TBLR1/TBL1 have been implicated in corepressor-coactivator exchange 
mechanisms and suggested to function as adaptor proteins for the recruitment of the 
ubiquitin conjugating/19S proteasome and the subsequent degradation of the NCoR/ 
SMRT/HDAC3 proteins, followed by recruitment of coactivators to different genes and 
this mechanism appears to be dependent on phosphorylated TBLR1/TBL1 (Perissi et 
al. 2004; Perissi et al. 2008), although the TBLR1/TBL1 dependent exchange 
mechanism on NR response elements needs further investigation. Moreover, 
TBLR1/TBL1 bind to hypo-acetylated histones (H2B and H4) and are suggested to be 
required for stable association of the repression complex with chromatin (Yoon et al. 
2003; Yoon et al. 2005)  
 
1.7.2.2 GPS2 
The core corepressor subunit GPS2 was initially demonstrated to suppress the 
RAS/MAPK kinase pathway in mammalian cells via interference with TNFα activated 
c-jun N-terminal kinase 1 (JNK1) (Spain et al. 1996; Jin et al. 1997). This was 
confirmed by Roeder and co-workers who provided evidence that a GPS2 containing 
NCoR/HDAC3 complex inhibited TNFα activated JNK1 (Zhang et al. 2002), although 
it needs to be clarified if JNK1 inhibition mediated via GPS2 occurs through repression 
of target genes involved in MAPK signaling or through interference with the canonical 
MAPK pathway upstream of JNK1. In addition to the inhibitory functions, GPS2 binds 
to papillomavirus E2 protein and p300 and appears to enhance the transcriptional 
activity of E2. The differential capacity of GPS2 was further established by interaction 
studies between p53 and GPS2 (in vitro and in vivo) demonstrating direct interaction 
between these proteins and overexpression of GPS2 was shown to significantly affect 
the transcriptional activity of p53 (Breiding et al. 1997; Peng et al. 2000; Peng et al. 
2001). Recently, GPS2 was discovered to display target gene selective activating and 
repressive functions in liver bile acid biosynthesis. GPS2 were shown to regulate the 
expression of CYP7A1 and CYP8B1 through interactions with LRH-1, FXR, HNF4α 
and SHP. On the CYP7A1 promoter GPS2 were found associated with the 
corepressors NCoR/HDAC3 together with SHP, LRH-1 and HNF4α thus functioning 
as a repressor. However, on the CYP8B1 promoter GPS2 were found associated with 
ligand activated FXR, HNF4α and CBP and in contrast to CYP7A1 function as a 
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coactivator (Sanyal et al. 2007). Subsequent studies have also shown that GPS2 
displays important function in ERα signaling. In MCF-7 breast cancer cells it was 
shown that GPS2 associates with SMRT upon 4-hydroxyl-tamoxifen mediated ERα 
repression and upon estradiol (E2) treatment on the pS2 promoter. Moreover, 
depletion of GPS2 in these cells, using siRNA, stimulated cell proliferation, although 
both in the presence and absence of ERα ligands, indicating that this effect is 
independent of ERα (Cheng and Kao 2009).   
   
1.7.2.3 RAP250 
Receptor activating protein RAP250 (Caira et al. 2000), also known as ASC-2, 
NCoA6, NRC, PRIP and TRBP (Mahajan and Samuels 2008), was originally isolated 
as a NR coregulator but has since then emerged as a coregulatory protein for several 
transcription factors, including CREB, p53 and NF-κB, among others. RAP250 
contains two activation domains (AD1 and AD2) and two LxxLL motifs. LxxLL-1 
(amino acids 887-891) has been shown to bind to numerous NRs including RAR, TR, 
ER, PPAR, GR, FXR, PXR, LXR, CAR and RXR. The second LxxLL motif (amino 
acids 1491-1495) appears to be more restrictive and binds to LXRα, LXRβ and FXR 
(Ananthanarayanan et al. 2011; Surapureddi et al. 2008; Lee et al. 2001; Mahajan and 
Samuels 2008; Surapureddi et al. 2008; Kim et al. 2009a). Deletion of RAP250 in mice 
results in embryonic lethality and could be explained by placental dysfunction and 
abnormalities in the liver, brain and heart (Kuang et al. 2002; Antonson et al. 2003; 
Mahajan et al. 2004). Given the specific interaction with LXR via the second NR-box; 
Kim et al. developed transgenic mice expressing a dominant negative fragment of 
RAP250, named DN2 (residue 1431-1511 (including LxxLL-2)). Interestingly, on 
high-cholesterol diet these mice displayed a highly homologous phenotype compared to 
the described phenotype in LXRα deficient mice, including accumulation of 
cholesterol in the liver (Kim et al. 2003) and impaired expression of several LXR target 
genes, including ABCG1 and ABCA1, in macrophages (Kim et al. 2009b). Moreover, 
recent data suggest that RAP250 recruits the histone H3 lysine 4 methyltransferases 
MLL3 and MLL4 proteins, subunits of the ASCOM (ASC-2 complex) complex (Goo 
et al. 2003), to ligand activated LXR target genes, which in turn leads to trimethylation 
of histone 3 lysine 4 (H3K4me3) (Lee et al. 2008). Furthermore, the ASCOM complex 
seems to play crucial role in RAR and FXR signaling pathways (Lee et al. 2006; Kim et 
al. 2009a). In addition to the ASCOM complex, RAP250 co-immunoprecipitates 
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together with Topoisomerase IIβ, PARP1 and DNAPK, among others proteins, in 
whole cells extracts from E2 treated MCF-7 cells. The TopoIIβ-containing complex is 
suggested to regulate initiation of transcription via dsDNA break formation, hence 
linking components of the DNA damage and repair machinery to NR mediated gene 
activation and RAP250 (Ju et al. 2006). 
 
 
 
 
 
 
 
1.7.3 SUMOylation 
Post-translational modifications of proteins involves attachments of various 
molecules and proteins, including among others, methylation, acetylation and covalent 
attachment of ubiquitin and ubiquitin-like modifiers (UBLs). One UBL, the small 
ubiquitin-like modifier (SUMO) has been shown to regulate various cellular processes, 
including DNA repair, replication and transcription via covalent attachment to substrate 
proteins, hence altering the properties of the substrate, such as the stability and activity. 
In mammals the SUMO family consists of three paralogues, SUMO-1 and the highly 
related SUMO-2 and SUMO-3 (Gareau and Lima). The conjugation of SUMO to an 
acceptor lysine of substrates consists of different enzymatic steps including, ATP-
dependent activation of SUMO by a heterodimeric E1 enzyme SAE1/2 (E1), transfer to 
the conjugating enzyme UBC9 (E2) and subsequent conjugation of the SUMO 
molecule to the substrate that usually requires an E3 ligase (E3). Several E3 ligases 
Figure 3. Schematic picture of important interaction domains in GPS2, NCoR and 
RAP250. TFs: Transcription factors, CoRNR: Corepressor nuclear receptor, RD: 
Repression domain, AD: Activation domain, SANT: Swi3-Ada2-NCoR-TFIIIB    
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have been identified, such as the PIAS proteins, RanBP2 and several HDACs (Geiss-
Friedlander and Melchior 2007).        
The first NR reported to be SUMOylated (SUMO-1) was the androgen receptor 
(AR) (Poukka et al. 2000), followed by the identification of several SUMOylated NRs, 
such as ER, PPAR, GR, LRH-1 and LXR. To date, SUMOylation of NRs appears to 
correlate with decreased transcriptional activity. Many identified SUMO-NRs contain 
an acceptor lysine within a classic consensus motif ΨKxE (Ψ=large hydrophobic 
amino acid and K=acceptor lysine). Interestingly, this consensus site is not present in 
LXRα and LXRβ, which are modified by the SUMO-2/3-HDAC4 pathway, in contrast 
to most other NRs, which are modified by the SUMO-1-PIAS1 pathway (Treuter and 
Venteclef 2010; Ghisletti et al. 2007). 
 
 
1.7.4 Transrepression of NCoR/SMRT  
NCoR and SMRT are important regulators of LPS induced primary response 
genes and appear to be associated to p50 (NF-kB) homodimers (Hargreaves et al. 
2009) or c-Jun homodimers (AP1) (Ogawa et al. 2004) under basal conditions. LPS 
stimuli lead to a p65/IKKε dependent phosphorylation of c-Jun and a TBLR1/TBL1 
dependent recruitment of the ubiquitin conjugating/19S proteasome and an exchange 
of corepressors and recruitment of coactivators to activate inflammatory gene 
transcription (Huang et al. 2009). The NCoR/SMRT corepressor clearance mechanism 
has been shown to be prevented by ligand activated NRs, such as LXR and PPARγ via 
a tethering process known as transrepression (Figure 4). Anti-inflammatory effects via 
transrepression was early shown to be mediated by the GR, although via different 
mechanisms compared to LXR and PPARγ (Glass and Saijo). Transrepression of the 
NCoR/SMRT complex was first identified in mouse macrophages, in which PPARγ 
was shown to repress LPS induced inflammatory genes in a SUMO dependent pathway 
(Pascual et al. 2005). Shortly after, LXRα and LXRβ was also identified to repress LPS 
induced inflammatory genes in macrophages via a parallel mechanism conjugated to 
SUMO-2/3 by the E3 ligase HDAC4 (see section 1.4.2), whereas PPARγ is conjugated 
to SUMO1 by the E3 ligase PIAS1 (Ghisletti et al. 2007).  
Interestingly, one SUMO acceptor site in LXRβ appears to be at residue 448 
and 434 in LXRα, which also is acetylated by SIRT1 (lysine 433 in LXRβ and lysine 
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432 in LXRα). Moreover, promoter studies of LPS stimulated macrophages have 
shown that most inflammatory target genes repressed by ligand activated LXRs 
contain NF-kB and AP-1 sites, but not LXREs, indicating that LXRs bind via protein-
protein interactions on TLR4 target genes (Ogawa et al. 2005). In addition to the 
SUMO-2-HDAC4-LXR pathway in macrophages a recent study suggests that ligand 
activated LXRβ is SUMOylated by PIAS1 and conjugated to SUMO-1 in IFNγ 
stimulated brain astrocytes inhibiting STAT-1 mediated inflammatory response (Lee et 
al. 2009). The above-mentioned data suggest that LXR, and other NRs as well; most 
likely utilize different strategies in different cell-types to prevent activation of 
inflammatory genes, although it is still an open question how SUMOylated LXRs dock 
to the corepressor complex.    
 
 
 
 
Figure 4. Anti-inflammatory transrepression by LXRs and PPARs. In addition to the 
conventional activation pathway, LXR and PPAR become postranslationally modified 
by SUMO and subsequently enter the transrepression pathway. Transrepression of 
inflammatory target genes involves docking to the corepressor complex and the thereby 
inhibition of degradation of the complex.    
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2 AIMS OF THESIS 
The general aim of this thesis was to characterise the combined influence of LXR in 
cholesterol metabolism and inflammation. In particular, our intentions were to: 
 
 
• Investigate the specific coregulator requirement of LXR target genes. 
• Understand the selective requirement of GPS2 for the LXR regulated target 
gene ABCG1 in cholesterol metabolism. 
• Investigate the anti-inflammatory action of LXR in the acute phase response 
and the connection to GPS2 and the core corepressor complex. 
• Investigate the role of LXR in colon and its involvement in inflammatory 
bowel disease. 
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3 RESULTS 
3.1 ARTICLE I: RAP250 IS A COACTIVATOR IN THE TRANSFORMING 
GROWTH FACTOR BETA SIGNALING PATHWAY THAT INTERACTS 
WITH SMAD2 AND SMAD3 
To identify RAP250 interacting proteins we screened a human ovary library 
using the yeast two-hybrid system with RAP250 (amino acids 1300-1771) as bait. 
Among other proteins we isolated clones that encoded the intracellular mediators of the 
canonical TGF-β signaling pathway, specifically the MH2 domain of Smad2 and its 
homolog Smad3 (derived from the Sma and MAD gene homologues in C. elegans and 
D. melanogaster). Smad2 and Smad3 have a similar structure consisting of an N-
terminal mad homology (MH) 1 domain and a C-terminal MH2 domain separated by a 
linker region (ten Dijke and Hill 2004). Domain mapping in yeast revealed that 
RAP250 interacted with Smad2/3 through a region between amino acids 1485-1512 
and interestingly this region includes the second NR box (NR2) that selectively binds to 
LXR. Moreover, mutation of NR2 completely abolished the interaction with Smad2. To 
further investigate the interaction between Smad2 and NR2 of RAP250 we made 
chimeras of RAP250 NR1 and NR2 interaction motifs, which revealed that in addition 
to NR2, the C-terminal flanking region was essential. The interaction between Smad2 
(MH2) and RAP250 (NR2) was also confirmed in mammalian cells. 
To further investigate the biological relevance of this interaction, TGF-β was 
activated in mouse embryonic fibroblasts (MEFs) isolated from wild type and RAP250 
knock-out embryos. Interestingly, the induced mRNA expression of the known TGF-
β target genes PA1-1 and connective tissue growth factor (CTGF) was reduced by 50% 
in RAP250-KO-MEFs compared to RAP250-WT-MEFs. Given the coregulatory 
function of RAP250 within LXR signaling pathways we also investigated if TGF-
β could influence the expression of LXR target genes. We treated human Huh7 liver 
cells and human U937 macrophages with TGF-β, T0901317 and both in combination 
and monitored the expression of ABCG1, ABCA1 and SREBP-1c. TGF-β alone had 
moderate effect on the ABCG1 expression, however co-treatment with TGF-β and 
T0901317 had a strong synergistic effect compared to T0901317 treatment alone. This 
effect was not seen at other LXR target genes, suggesting a promoter specific role for 
TGF-β upon LXR activation on the ABCG1 promoter. The above experimental setup 
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in LXR-KO-MEFs failed to synergistically induce the expression of ABCG1 whereas 
this effect was intact in LXR-WT-MEFs. 
 
 
        
3.2 ARTICLE II: GPS2 IS REQUIRED FOR CHOLESTEROL EFFLUX BY 
TRIGGERING HISTONE DEMETHYLATION, LXR RECRUITMENT, 
AND COREGULATOR ASSEMBLY AT THE ABCG1 LOCUS   
Recent work from our laboratory suggests that the core corepressor subunit GPS2 
has dual (repressive and activating) functions in cholesterol homeostasis. Focused on 
this, we applied an unbiased approach and depleted the expression of GPS2 in human 
hepatic HepG2 cells and THP-1 macrophages to study the impact of GPS2 in LXR 
signaling pathways.  
Interestingly, siRNA mediated knockdown of GPS2 in these cells significantly 
reduced LXR induced mRNA expression of ABCG1 while not affecting other known 
LXR target genes (e.g. ABCA1, SREBP-1c). In contrast, depletion of TBLR1, another 
member of the NCoR corepressor complex, reduced the expression of all LXR target 
genes in the presence of LXR ligand. Depletion of NCoR or TBL1 did not affect any of 
the LXR regulated target genes under these conditions. Moreover, protein expression of 
ABCG1 in macrophages using siRNA against GPS2 confirmed our mRNA expression 
data. To demonstrate if knockdown of GPS2 was of physiological relevance, we 
measured the efflux of cholesterol to HDL acceptor (ABCG1 efflux pathway) in 
macrophages. Ligand activated LXR increased the cholesterol efflux, whereas 
depletion of GPS2 abolished the increased LXR dependent cholesterol efflux. 
Collectively, these data indicates that GPS2 is selectively required for LXR mediated 
expression and activation of ABCG1. 
Above observations encouraged us to explore the recruitment of GPS2 in relation 
to other coregulators at the promoter regions of human ABCG1 and ABCA1 using 
chromatin immunoprecipitation (ChIP) assays. In the absence of ligand we identified 
LXR together with the corepressor components; NCoR, HDAC3, TBLR1, TBL1 and 
GPS2 on the ABCA1 promoter. Activation of LXR caused their dissociation (except 
TBLR1) and coactivators were recruited (e.g. CBP, SRC-1), which is indicative of a 
conventional LXR-dependent coregulator exchange mechanism. Intriguingly, on the 
ABCG1 promoter in the absence of ligand, neither LXR nor GPS2 were present on the 
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ABCG1 promoter, however, upon ligand treatment both LXR and GPS2 were recruited 
to the promoter linking GPS2 to transcriptional activation on the ABCG1 promoter. 
These results were seen in both HepG2 and THP-1 cells and confirmed in vivo in mice 
liver. Moreover, GPS2 was not recruited to the ABCG1 promoter in LXRαβ-/- mice 
treated with LXR ligand indicating that binding of LXR is essential for GPS2 
recruitment. Collectively, these observations suggest that GPS2 has specific functions 
linked to transcriptional activation together with LXR on the ABCG1 promoter and 
these activities appear to be promoter specific and conserved between human and 
mouse. 
In an attempt to elucidate if the above-mentioned effects were mediated via direct 
interactions between LXR and GPS2 we utilized various direct protein-protein 
interaction assays. The characterisation revealed a ligand-enhanced interaction of GPS2 
with both LXRα and LXRβ, and GPS2 appears to bind a surface distinct from AF-2 in 
the LXRs. Furthermore, we identified a minimal LXR interacting GPS2 domain (a.a. 
150-264) lacking LXXLL motifs.  
ABCA1 appears to utilize one LXRE on the promoter upon activation, while 
ABCG1 in addition to the promoter LXRE, contains an intronic enhancer LXRE (Sabol 
et al. 2005). To test the functionality of the enhancer we performed time resolving ChIP 
assays against both LXREs and this revealed that LXR and GPS2 were recruited to 
both the ABCG1 promoter and enhancer with a nearly identical profile, thus indicating 
a functional link upon activation. To further substantiate this data we employed 
chromosome conformation capture (3C) assays, which confirmed that activation of 
LXR triggers intrachromosomal communication between the promoter and enhancer 
LXRE. Furthermore, depletion of GPS2 abolished the ligand dependent recruitment of 
LXR to ABCG1 and the subsequent communication between the promoter/enhancer. In 
contrast, depletion of GPS2 did not affect the LXR recruitment or coactivator assembly 
on the ABCA1 promoter.  
Initial ChIP data indicated that ABCA1 was acetylated (H3Ac) in the absence of 
LXR ligand (i.e activation mark) and this was not seen on the ABCG1 promoter. Based 
on this we employed a time-resolving ChIP assay regarding H3 acetylation and H3K9 
dimethylation (i.e. repression mark) on ABCA1 and ABCG1 promoters. Remarkably, 
on ABCG1 LXR ligand induced a rapid H3K9 demethylation and acetylation, whereas 
on ABCA1 the repression mark H3K9me2 was absent together with acetylated 
chromatin (H3Ac). Moreover, we also detected the presence of the methylase G9a in 
the absence of ligand on the ABCG1 promoter/enhancer and upon activation several 
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demethylases were recruited (KDM1 (LSD1), KDM3A (JHDM2A) and KDM4A 
(JHDM3A)). Collectively, these data suggest that the hypoacetylated and 
hypermethylated (H3K9) chromatin state on ABCG1 could function as a barrier that 
prevents LXR binding to DNA and upon ligand activation demethylases are recruited 
to facilitate demethylation and binding of LXR to DNA, a process requiring GPS2.  
 
 
 
3.3 ARTICLE III:GPS2-DEPENDENT COREPRESSOR/SUMO PATHWAYS 
GOVERN ANTI-INFLAMMATORY ACTIONS OF LRH-1 AND LXRβ IN 
THE HEPATIC ACUTE PHASE RESPONSE 
Lipid-sensing NRs appear to play important roles in the inflammatory response 
and LXR has been shown to inhibit the expression of several LPS induced pro-
inflammatory genes in macrophages via a SUMO dependent tethering mechanism, 
preventing the dissociation of the NCoR/HDAC3 corepressor complex, a mechanism 
referred as transrepression (Ghisletti et al. 2007). Moreover, ligand activated LXR 
displays anti-inflammatory actions in hepatocytes (Blaschke et al. 2006), and recently 
LRH-1 was found to antagonize several cytokines in the liver (Venteclef et al. 2006; 
Venteclef and Delerive 2007). The link between LXR, GPS2 and the NCoR/HDAC3 
corepressor complex, together with our results in article II encouraged us to investigate 
the mechanism behind the anti-inflammatory actions of LXR and LRH-1 in the acute 
phase response (APR) in human hepatocytes and mice.   
To induce an APR we stimulated human primary hepatocytes with IL-1β and IL-
6 and as expected the expression of several APPs was induced. However, pre-treatment 
with the LXR/LRH-1 ligands (GW3965/GR8470) inhibited the expression of the APPs, 
except plasminogen activator inhibitor 1 (PAI-1). Furthermore, ChIP assays in Huh7 
cells revealed that LXR/LRH-1 were recruited to the NCoR/ HDAC3/GPS2/TBLR1 
corepressor complex on the SAA and haptoglobin promoters in ligand treated cells 
under inflammatory conditions, thus preventing the dissociation of the complex. 
Additionally, LXR/LRH-1 was not recruited in the absence of ligand under 
inflammatory conditions indicating that ligand activation induces the recruitment of 
LXR/LRH-1 to the APR promoters. Interestingly, LXR appears to function in the 
absence of RXR as observed by our ChIP data. 
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  Next we investigated if recruitment of LXR/LRH-1 was SUMO dependent. 
Knockdown (KD) studies (siRNA) of SUMO-1 and SUMO-2/3 in Huh7 cells revealed 
that KD of SUMO-1 affected the transrepressive activity of LRH-1, whereas KD of 
SUMO-2/3 affected the LXR transrepressive pathway, as previously shown in 
macrophages. Furthermore, this data was strengthened by the fact that SUMO-2/3 
together with LXR and SUMO-1 together with LRH-1, were recruited to the 
haptoglobin promoter.  
To investigate the SUMO dependent transrepression pathway in vivo, we treated 
C57BI/6J (wild type (WT)) and LXRαβ-/- mice with LPS (+/- GW3925) to induce an 
inflammatory response. Activation of LXR significantly reduced the mRNA expression 
of SAA, haptoglobin and CRP in LPS treated mice, which was confirmed at protein 
level. Importantly, LXRαβ-/- mice treated with ligand under inflammatory conditions 
failed to reduce the mRNA expression of APR genes, which prompted us to investigate 
if both LXR subtypes were capable to transrepress APR genes in vivo. Under the same 
conditions as for LXR WT and LXRαβ-/-, LXRα-/- mice transrepression of APR genes 
was observed in LXRα-/- mice, whereas no transrepression was seen in LXRβ-/- mice, 
thus indicating that LXRβ selectively inhibits hepatic APR, both in vivo and in vitro. In 
addition, we also substantiated the mRNA data with ChIP assays from liver samples. 
As expected, LXR was recruited to the haptoglobin promoter in WT and LXRα-/- mice 
but was not recruited in LXRαβ-/- and LXRβ-/- mice. 
Since GPS2 is linked to the NCoR/HDAC3 corepressor complex and in view of 
our results in article II we investigated the importance of GPS2 in the APR pathway. 
Using various direct protein-protein assays together with ChIP assays and siRNA 
transfection we could conclude the following: 
 
• Repression of APR genes requires NCoR and recruitment of LXR or LRH-1 
depends on GPS2.  
• The N-terminal domain of GPS2 interacts with NCoR and this interaction is 
crucial for recruitment of LXR and LRH-1. 
• GPS2 binds to SUMO-1 and SUMO-2 via a domain located in the N-terminal 
part of GPS2, suggesting that SUMOylated LXR and LRH-1 binds to the 
corepressor complex via docking to GPS2 and this interaction depends on 
both the SUMO molecule and the receptor. 
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3.4 ARTICLE IV: THE OXYSTEROL RECEPTORS, LXRα AND LXRβ, 
PROTECT AGAINST DSS-INDUCED COLITIS IN MICE 
Given the fact that LXRs could be highly interesting candidates for treatment of 
inflammatory conditions, supported by their protective role(s) in many inflammatory 
conditions and diseases, and based upon our findings in article III, we wanted to 
investigate the role of LXR in colon and its involvement in IBD.   
We used DSS-induced colitis, a common model in mice used to study colitis, to 
examine the role of LXR. We used C57BI/6J mice (wild type (WT)), LXRα-/-, LXRβ-/- 
and LXRαβ-/- mice. WT mice were pre-treated with the synthetic LXR agonist 
(GW3965) (30mg/kg/day) or vehicle by gavage for 4 days and 2.5% DSS was added in 
the drinking water (±GW3965) for 9 days and 7 days for LXR KO mice. At day 9 the 
WT mice had lost 13% of their body weight upon DSS treatment, while no significant 
effect of GW3965 was observed. The onset of loss of body weight was earlier in LXR 
KO mice and at day 7 the body wight was reduced 15%, 2% and 14% in LXRαβ-/-, 
LXRα-/- and LXRβ-/- mice. In comparison, only small changes in symptoms and 
phenotypes were observed in WT mice at day 7.  
LXRαβ-/- and LXRβ-/- mice exhibited a severe phenotype including reduced colon 
length, increased rectal bleeding and diarrhea. These clinical markers were less 
pronounced in WT and LXRα-/- mice. Histopathological examination of the colon 
revealed that DSS treatment caused severe ulceration, disruption of crypts and 
hyperplasia, in all genotypes, although this was more pronounced in LXRαβ-/- and 
LXRβ-/- mice. Moreover, DSS caused a dramatic increase in infiltration of neutrophil 
granulocytes and macrophages. Interestingly, infiltration of macrophages was 
significantly increased in KO mice – particularly in the LXRαβ-/- mice at basal 
conditions.  
Further we investigated the possibility that activation of LXR could influence the 
weight recovery from colitis. Thus, mice were given 2.5% DSS and upon 
approximately 10% weight reduction the DSS were withdrawn from water and body 
weight monitored for 8 days. The GW3965 treated group showed a trend towards a 
faster recovery of weight compared to untreated animals. The LXRαβ-/- mice recovered 
significantly slower compared to WT-GW3965 animals. In addition, WT-DSS-
GW3965 mice had significantly lower immune response at the endpoint compared to 
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WT-DSS mice, revealed by lower mRNA expression of several known pro-
inflammatory genes, such as IL-6, TNF-α and MCP-1.  
The initiation of the innate immune response in IBD involves activation of TLRs 
and NODs, found on the epithelium, which increases the activity of NF-κB and the 
subsequent expression of several cytokines and chemokines to attract different immune 
cells. Given the known transrepressive function of LXR, we treated Colo205 human 
colorectal adenocarcinoma cells with GW3965 over night followed by TNFα. 
Interestingly, activation of LXR completely abolished the induced auto-induction of 
TNFα, reduced the expression of IL-8 by 50% and the expression of caspase-1 by 80%. 
Moreover ChIP assay on the IL-8 promoter revealed a significant recruitment of ligand 
activated LXR under inflammatory conditions. 
Extraintestinal manifestations are poorly investigated in association with IBD, but 
is a highly interesting effect of colitis and a recent study reported that reduced levels of 
hepatic stearoyl-CoA desaturase 1 (SCD1), which is a known LXR target gene, 
exacerbate colitis in DSS treated mice (Chen et al. 2008). To investigate this we treated 
WT and LXRαβ-/- mice with 2.5% DSS for 9 and 7 days, respectively, and the protein 
levels of SAA in plasma were determined using ELISA. DSS increased the SAA levels 
in all groups, however the response was stronger in LXRαβ-/- mice, compared to WT 
mice. Moreover, activation of LXR significantly repressed the expression of SAA in 
the blood in this colitis model in agreement with paper III. We also observed that the 
reduced expression of SCD1 (and SREBP1c) upon DSS treatment was completely 
restored by activation of LXR.  This suggests that activation of LXRs could prevent 
extraintestinal symptoms of colitis and therefore have additional roles in protecting 
against IBD. 
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4 DISCUSSION 
The dual impact of LXRs in inflammatory and metabolic pathways makes them 
intriguing factors to increase our understanding how metabolic diseases develop an 
inflammatory component and vice versa. The role of LXR in the cholesterol transport is 
well established and numerous studies have highlighted the importance of LXR in RCT 
and the development of cardiovascular disease. In addition, LXRs display anti-
inflammatory effects in macrophages and other immune cells, which might contribute 
to the protective role of LXRs in development of atherosclerosis. The novel functions 
of LXRs in the innate and adaptive immune response is intriguing and potentially opens 
up new strategies to treat different chronic inflammatory conditions, such as IBD, 
arthritis and atherosclerosis. However, one complication towards the development of 
compounds targeting LXR is the hepatic lipogenic activity, presumably by activated 
LXRα, which raises the triglyceride levels in the liver and plasma. Consequently, 
subtype specific compounds that selectively targeting LXRβ have emerged as one 
possible strategy for drug development. Indeed, LXRa-/- / apoE-/- double knockout mice 
treated with GW3965 showed reduced atherosclerosis, presumably by an increased 
activity of ABCA1 and ABCG1 in both intestine and macrophages. In addition, a 
decreased expression of inflammatory markers was observed in macrophages (Bradley 
et al. 2007). Moreover, N-acylthiadiazolines have been described as LXRβ selective 
ligands (Molteni et al. 2007). The anti-inflammatory and immuno-modulatory action of 
LXRs includes several different cell types in both the innate and adaptive immune 
response and recent data suggest that in addition to subtype specific compounds, 
pathway selective (transrepression vs. transactivation) compounds could provide an 
additional selective strategy (Chao et al. 2008). Intriguingly, some oxysterols appears to 
function in both pathways whereas some only enters the transactivation pathway 
(Ghisletti et al. 2007). Collectively, this suggests that in order to develop compounds 
with a “narrow spectrum” it is crucial to identify the mechanisms (i.e. the interplay 
between NRs and coregulators) behind these differences in inflammatory and metabolic 
pathways. 
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In this thesis we have extend the knowledge of the specific coregulator 
requirement of LXR in cholesterol metabolism and the anti-inflammatory actions of 
LXR and LRH-1 in the hepatic APR. Although the effect of LXRs in different 
transactivation pathways has been intensively studied, the molecular mechanisms still 
remains largely unexplored. The molecular details by which LXR and other NRs 
transrepress inflammatory target genes in macrophages was initially described by Glass 
and colleagues and in this thesis we found that this mechanism also occur outside the 
immune system, in liver cells. Furthermore, we present in vivo data suggesting that in 
addition to liver cells and macrophages this mechanism, although not studied in detail, 
also occur in epithelial cells.    
  
In article I we identified the intracellular mediators of the canonical TGF-β 
signaling pathway, Smad2 and Smad3, as RAP250 interacting proteins and this 
interaction appears to be mediated via the MH2 domain of the Smad proteins and the 
second NR-box in RAP250. A possible role for RAP250 in the regulation of PAI-1 
could be as a linker between CBP/p300 and mediator complexes since both RAP250 
and Smad proteins are known to associate with CBP, p300 and the mediator 
components. Furthermore, using RAP250-KO-MEFs and LXR-KO-MEFs we suggest 
that RAP250 is a novel coregulator for selected TGF-β target genes and that TGF-
β appears to have a pronounced impact on the ABCG1 expression upon LXR 
activation. RAP250 is a large protein with two LXXLL motifs and has no intrinsic 
enzymatic activity. RAP250 appears to selectively bind LXR via NR2 and data suggest 
that RAP250 is an important factor in LXR signaling pathways (Kim et al. 2003). 
Furthermore, RAP250 is also linked to trimethylation of H3K4 (H3K4me3) (Lee et al. 
2008), which is often found at active promoters. This data suggest that RAP250 might 
function as a scaffold, thus recruiting LXR via NR2 to the ASCOM complex in order to 
activate transcription.  
Recent studies have shown that activation of the TGF-β pathway increases 
cholesterol efflux through upregulation of ABCA1 and ABCG1 (Argmann et al. 2001; 
Panousis et al. 2001). Based on our findings, we suggest that this effect partly might 
depend on a functional LXR pathway. Future studies are required to clarify if this 
crosstalk is Smad dependent via indirect or direct interactions. Furthermore we do not 
exclude the possibility that activation of different MAPK pathways through TGF-β is 
required.  
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In article II we describe major differences between the LXR regulated 
cholesterol transporters ABCG1 and ABCA1 at the molecular level. We have 
identified, upon ligand activation, a GPS2 dependent LXR recruitment to the ABCG1 
promoter, which potentially could stimulate efforts to develop LXR agonists that target 
LXR-GPS2 interactions. Such agonists would promote cholesterol efflux via ABCG1 
but fail to upregulate the lipogenic genes regulated by LXR, thus overcome the 
unwanted side-effects such as elevated fatty acid and triglyceride levels. Furthermore, 
activation and recruitment of LXR induce a communication between the promoter and 
enhancer of ABCG1. In contrast, on the ABCA1 promoter LXR seems to utilize the 
conventional LXR-dependent coregulator exchange mechanism. In the absence of 
ligand LXR is bound to the LXRE on ABCA1 and associated with corepressors. Upon 
binding of ligand the repressor complex dissociates from LXR and different 
coactivators are recruited in order to activate the expression of ABCA1. In addition, we 
also link GPS2 and H3K9 demethylation via recruitment of several demethylases to 
LXR dependent activation of ABCG1. This could explain the absence of LXR on 
ABCG1 without ligand i.e. binding of LXR to repressed chromatin is prevented. Most 
likely, ChIP-seq. studies in the near future will reveal other LXR target genes that 
utilize a strictly ligand dependent recruitment of LXR as seen on ABCG1 and it will be 
highly interesting to see if GPS2 co-enriches close to LXR binding sites at these sites. 
 
In article III we investigate the anti-inflammatory actions of LXR and LRH-1 in 
the hepatic acute phase response. During the APR the plasma level of HDL decreases 
and the major apolipoprotein of normal HDL (apolipoprotein AI) is replaced by SAA. 
The acute phase HDL (SAA-HDL) is believed to be pro-atherogenic and the altered 
properties of acute phase HDL have significant impact on cholesterol transport and 
cholesterol efflux. Interestingly, in article II we link GPS2 to LXR dependent 
regulation of cholesterol efflux in macrophages and in this study we link the 
metabolic receptors LXR and LRH-1 to anti-inflammatory pathways in the APR, thus 
connecting HDL metabolism and inflammation.  
Recently, it was shown that SUMOylated LXRs are recruited to inflammatory 
genes in macrophages (Ghisletti et al. 2007). However, the mechanism behind how 
SUMOylated LXRs dock to the corepressor complex remained unanswered. Our data 
indicates that GPS2 might function as a mediator for SUMOylated LXRβ and LRH-1, 
and other NRs as well, thus answering the “docking” issue. Moreover, we show that 
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LXR is recruited without the heterodimeric partner RXR. LXR appears to be 
SUMOylated in the LBD, which theoretically could eliminate the interaction 
(conformational changes) with RXR, and the established function of LXR as a direct 
DNA binding factor, thus creating a pool of SUMOylated LXRs primed for the 
transrepression pathway. Recently, Huang et al. identified an alternative docking 
mechanism in mouse macrophages, which included a SUMO-LXRβ dependent 
interaction with CORO2A. Moreover, in addition to the described TBLR1/TBL1 
dependent exchange mechanism, the derepression step also appears to involve 
recruitment of actin through CORO2A, and the subsequent clearance of the corepressor 
complex from inflammatory genes (Huang et al. 2011). This suggests that the cellular 
environment is of great importance (i.e. macrophage and liver) and apparently more 
work is required to identify the mechanisms behind these disparities. Finally, emerging 
data suggest that there are species differences in terms of anti versus pro-inflammatory 
functions of LXR and PPARs (Fontaine et al. 2007; Hall and McDonnell 2007), again 
underscoring the importance to elucidate the mechanisms (i.e. inflammatory stimuli 
(LPS, TNF-α), ligand specificity, short/long-term treatment) behind the NR dependent 
transrepression pathways.   
 
In article IV we link LXR to anti-inflammatory actions in epithelial cells, which is 
important components in the inflammatory bowel disease. IBD is a complex disease 
involving an early innate immune response via epithelial cells, dendritic cells (DC) and 
macrophages and activation of the NF-κB pathway in epithelial cells via TLRs and 
NODs is crucial given the connection with the luminal flora. In this study we show that 
ligand activated LXRs repress several pro-inflammatory factors, including TNFα and 
IL-8, induced by TNFα in Colo205 epithelial cells and most likely via a related 
mechanism as in macrophages and in paper III (liver cells), although the molecular 
mechanisms were not studied in detail. This suggests that LXR has important anti-
inflammatory function in epithelial cells and subsequently reduces the recruitment of 
immune cells via transrepression of cytokines and chemokines. Moreover, in LXRαβ-/- 
mice a higher content of macrophages was seen in the colon under basal conditions, 
which partly could be explained by the above-mentioned mechanism. We also found 
that LXRβ deficient mice displayed a more severe phenotype when challenged with 
DSS, such as ulceration and rectal bleeding, however this was also seen in LXRα mice, 
although not that pronounced. This suggests that both subtypes have protective 
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functions in IBD. Based upon recent findings, we speculate that LXRα might be 
involved in the innate response, whereas LXRβ is the crucial factor in the acquired 
response. LXR has important functions in lymphocytes (Bensinger et al. 2008; 
Geyeregger et al. 2009) and activation of LXR appears to inhibit the differentiation of 
T-cells via induced transcription of the Srebp1 target gene (Cui et al. 2011). The fact 
that IBD has been viewed as a T-cell driven disease also suggests that LXRs are 
possible targets in the acquired response to prevent the development of IBD. In 
conclusion, our observations suggest that LXR protects against IBD, through 
transrepressive mechanisms in the innate response in epithelial cells and potentially, as 
shown by others, through repressive functions in the acquired response.  
 
In summary, our studies have identified novel molecular mechanisms of LXR 
signaling in metabolism and inflammation. Modulation of LXR activity affects the 
expression profiles of both metabolic pathways and inflammatory signaling 
pathways. Our observations support the notion that LXRs are attractive drug targets 
for therapeutic intervention of metabolic disorders and inflammatory diseases. 
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5 CONCLUSIONS  
In this thesis we have investigated the specific coregulator requirement and dynamics 
of LXR target genes in cholesterol metabolism and the anti-inflammatory actions of 
LXR in liver and colon and the conclusion from these articles can be summarised as 
follows:  
 
Article I 
• RAP250 has a critical role in the canonical TGF-β pathway and interacts with 
the intracellular mediators, Smad2 and Smad3.  
• The interaction between RAP250 and Smad2/3 is dependent upon the second 
LXXLL motif in RAP250 and the MH2 domain in Smad2/3.  
• Activation of the TGF-β and LXR signaling pathways synergistically regulates 
the expression of the LXR target gene ABCG1. 
 
Article II 
• GPS2 is selectively required for LXR induced transcription of ABCG1 and 
depletion of GPS2 diminishes ABCG1-mediated cholesterol efflux in 
macrophages. 
• There are fundamental differences between ABCG1 and ABCA1 with regard to 
GPS2 and other coregulators. 
• GPS2 and LXR authorise histone 3 lysine 9 demethylation-coupled activation 
of ABCG1. 
• Activation and recruitment of LXR induces a communication between promoter 
and enhancer elements of ABCG1. 
• LXR and GPS2 interactions appear to be AF-2 independent. 
 
Article III 
• Ligand dependent SUMOylation of LXR and LRH-1 inhibits the hepatic acute 
phase response, thus preventing the dissociation of the NCoR corepressor 
complex. 
• GPS2 mediates the interaction between SUMOylated NRs and the NCoR 
corepressor complex. 
• Transrepression by LXR appears to exclude the heterodimeric partner RXR.  
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• LXR is recruited to APR promoters in LXR WT and LXRα mice, but not in 
LXRβ mice indicating that LXRβ selectively inhibits hepatic APR. 
• GPS2 interacts with NCoR through the N-terminal domain. This domain also 
binds to SUMO-1 and SUMO-2 and this interaction depends on both the 
SUMO molecule and LXR/LRH-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic picture emphasising the major conclusions in this thesis. In the 
hepatic APR, LXR-SUMO-2 and LRH-1-SUMO-1 docks to the NCoR corepressor 
complex via the subunit GPS2 and prevents the clearance of the repressor complex, 
thereby repressing the expression of APR genes. The anti-inflammatory actions of LXR 
in epithelial cells are presumably related to this mechanism. In macrophages and liver 
cells LXR regulates the expression of ABCG1 through an alternative mechanism, which 
is dependent on GPS2. In contrast, on the ABCA1 promoter LXR utilise the classical 
LXR dependent coregulator exchange mechanism.        
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Article IV 
• DSS-induced colitis in C57BI/6J (WT), LXRα-/-, LXRβ-/- and LXRαβ-/- mice 
caused a particularly severe phenotype in LXRβ-/- and LXRαβ-/- mice, this was 
also seen in LXRα-/- mice, although not that pronounced. 
• DSS recovery studies revealed that LXRαβ-/- mice recovered significantly more 
slowly compared to C57BI/6J mice treated with GW3965. 
• Activation of LXR in human colon cells under inflammatory conditions 
repressed the expression of several pro-inflammatory factors and LXR is 
recruited to the IL-8 promoter. 
• The above point could be the reason for increased infiltration of macrophages in 
LXR KO mice at basal level. 
• The increased infiltration of macrophages could be the reason for a more severe 
immune response to DSS treatment in LXR KO compared to WT mice. 
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